Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Press Release

BlissCo Advances E-Commerce Program Ahead of Cannabis Legalization -- CFN Media


Posted on: 27 Jul 18

SEATTLE, July 27, 2018 (GLOBE NEWSWIRE) -- CFN Media Group (“CFN Media”), the leading agency and financial media network dedicated to the North American cannabis industry, announces publication of an article discussing BlissCo Cannabis Corp.'s (CSE:BLIS) recent moves to create a vibrant and convenient online experience for its customers. The cannabis industry lags behind most other industries in online adoption, mostly due to legal issues that limit free commerce. That is all changing quickly, and BlissCo is laying the groundwork to take full advantage of the marketing and sales possibilities offered in the online environment. The company’s recent agreement with Namaste Technologies represents a major step forward as the company implements its comprehensive plan focused on cannabis product development, branding, and distribution.

With advances in technology over the last few years, ecommerce has been taking a larger and larger chunk of retail sales. E-commerce sales as a percentage of total retail sales stand around 10% in the United States, and that number is growing about 15% per year. In Canada, it’s about 9% of sales with a 30% growth rate. E-commerce use is especially prevalent in younger generations, making it an essential component of growth strategies. The message is clear - sell online or be left behind.

E-Commerce Development

BlissCo is implementing a somewhat unique approach in comparison to other Canadian licensed producers. Rather than ramping up production capacity ahead of full legalization, the company has chosen to focus on higher margin products like oils and medicines, developed and packaged and distributed through its state of the art, high volume production facility. On the sales end, e-commerce will likely play a large role in driving revenues.

To that end, BlissCo is engaging Namaste to develop its e-commerce platforms. Namaste is one of the world’s largest online retailers of cannabis accessories, with more than 30 websites serving more than 20 countries. More importantly, Namaste is on the cutting edge of e-commerce technology, and BlissCo intends to use some of that tech to create its own vibrant online environment.

One of Namaste’s innovations, NamasteMD.com, is the first Health Canada compliant telemedicine app. Using the portal, users can sign up, connect with a doctor, get their medical cannabis recommendations, and arrange for the delivery of prescriptions. The two companies have agreed to whitelabel the app for BlissCo’s own patients, promising to make the medical cannabis experience as user friendly as possible. The agreement also entails access to cannabis delivery services through Namaste’s partially owned subsidiary, Pineapple Express Delivery.

Namaste also has developed artificial intelligence and machine learning capabilities that it will use to personalize and maximize the experience for BlissCo customers. For instance, BlissCo users could be given product recommendations based on personal symptoms and checked against a database of user-generated inputs on the effect of various cannabis strains. The more effective and efficient BlissCo’s online environment becomes, the more likely it is that customers will stay.

The two companies really believe in each other, so much so that Namaste’s co-founder and CEO, Sean Dollinger, is taking a seat on BlissCo’s board. Having Mr. Dollinger’s unique entrepreneurial spirit, combined with his technology and e-commerce experience, should be helpful as BlissCo implements its Canadian, and eventually global, medical and retail strategies.

The Bigger Picture for BlissCo

BlissCo is putting together a complete ecosystem comprised of cannabis product development, packaging, branding and distribution. Recognizing its own capabilities and limitations, the company is not afraid to strategically partner to address shortcomings. From cannabis supply agreements with other licensed producers to jumpstart its cannabis flower inventory, to the deal with Namaste and the appointment of Mr. Dollinger, BlissCo is demonstrating its ability to broaden its reach while remaining true to the original vision of the company.

In another indication of the company’s broader vision, BlissCo recently announced major progress toward getting its facility Eudralex GMP certified. This particular Good Manufacturing Practices certification is the most stringent in the world, and necessary if the company hopes to export products to Europe. Coming on the heels of BlissCo’s previously announced partnership with a German distributor, it is clear that the company intends to do just that as quickly as possible, pending the proper licenses and certifications. Germany is Europe’s largest medical marijuana market, offers government insurance for approved cannabis treatments, and is expected to rely mostly on imports for the next several years as domestic levels of cannabis production slowly rise. It’s a good place for BlissCo to start implementing its globally- and vertically-integrated plan.

Please follow the link to read the full article: http://www.cannabisfn.com/blissco-advances-e-commerce-program-ahead-cannabis-legalization/

About CFN Media

CFN Media (CannabisFN) is the leading agency and financial media network dedicated to the global cannabis industry, helps companies operating in the space attract investors, capital, and publicity. Since 2013, private and public cannabis companies in the US and Canada have relied on CFN Media to grow and succeed.

Learn how to become a CFN Media client company, brand or entrepreneur: http://www.cannabisfn.com/featuredcompany

Download the CFN Media iOS mobile app to access the world of cannabis from the palm of your hand: https://itunes.apple.com/us/app/cannabisfn/id988009247?ls=1&mt=8

Or visit our homepage and enter your mobile number under the Apple App Store logo to receive a download link text on your iPhone: http://www.cannabisfn.com

Disclaimer

CannabisFN.com is not an independent financial investment advisor or broker-dealer. You should always consult with your own independent legal, tax, and/or investment professionals before making any investment decisions. The information provided on http://www.cannabisfn.com (the ‘Site’) is either original financial news or paid advertisements drafted by our in-house team or provided by an affiliate. CannabisFN.com, a financial news media and marketing firm enters into media buys or service agreements with the companies that are the subject of the articles posted on the Site or other editorials for advertising such companies.  We are not an independent news media provider. We make no warranty or representation about the information including its completeness, accuracy, truthfulness or reliability and we disclaim, expressly and implicitly, all warranties of any kind, including whether the Information is complete, accurate, truthful, or reliable. As such, your use of the information is at your own risk. Nor do we undertake any obligation to update the items posted. CannabisFN.com received compensation for producing and presenting high quality and sophisticated content on CannabisFN.com along with financial and corporate news.  

The above article is sponsored content. Emerging Growth LLC, which owns CannabisFN.com and CFN Media, has been hired to create awareness. Please follow the link below to view our full disclosure outlining our compensation: http://www.cannabisfn.com/legal-disclaimer/

CFN Media
Frank Lane
206-369-7050
flane@cannabisfn.com

 

GlobeNewswire
globenewswire.com

Last updated on: 30/07/2018

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.